In their study of Japanese patients, Hakozaki et al. reported differences in GM composition between patients with advanced NSCLC treated with anti-PD-1/PD-L1 who experience ≥ grade 2 irAEs of any tissue or organ and those who experienced mild (grade 1) or no irAEs [119]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.